Industry Research Reports

Home > Reports > Medical Care > RNAi for Therapeutic- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

RNAi for Therapeutic- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Industry: Medical Care

Published Date: 2025-01-16

Pages: 105 Pages

Report ld: 3474070

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

RNAi for Therapeutic Market Size(US$)

CAGR 2025-2031

43.1%

Market Size,2031

USD 4,272

Million

Market Snapshot

Market Size in 2025 (Value)

US$ 498 million

Market Forecast in 2031(Value)

US$ 4,272 million

CAGR

43.1%

Years Considered

2020-2031

Base Year

2025

Forecast Period

2025-2031

Source: Secondary research, interviews with experts, and QYResearch analysis

The global market for RNAi for Therapeutic was estimated to be worth US$ 358 million in 2024 and is forecast to a readjusted size of US$ 4272 million by 2031 with a CAGR of 43.1% during the forecast period 2025-2031.

RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.

Global RNAi for Therapeutic key players include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, etc. Global top five manufacturers hold a share over 85%.

US is the largest market, with a share over 75%, followed by EU, which has a share about 3%.

In terms of product, siRNA is the largest segment, with a share over 55%. And in terms of application, the largest application is Cancer, followed by HBV, Cardiovascular, etc.

This report aims to provide a comprehensive presentation of the global market for RNAi for Therapeutic, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of RNAi for Therapeutic by region & country, by Type, and by Application.

The RNAi for Therapeutic market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RNAi for Therapeutic.

MARKET SEGMENTATION

By Company

Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
miRagen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

siRNA
miRNA
shRNA

Segment by Application

Cancer
Cardiovascular
HBV
Others

biaoTi CHAPTER OUTLINE

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of RNAi for Therapeutic company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of RNAi for Therapeutic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of RNAi for Therapeutic in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Market Overview

1.1 RNAi for Therapeutic Product Introduction

1.2 Global RNAi for Therapeutic Market Size Forecast (2020-2031)

1.3 RNAi for Therapeutic Market Trends & Drivers

1.3.1 RNAi for Therapeutic Industry Trends

1.3.2 RNAi for Therapeutic Market Drivers & Opportunity

1.3.3 RNAi for Therapeutic Market Challenges

1.3.4 RNAi for Therapeutic Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global RNAi for Therapeutic Players Revenue Ranking (2024)

2.2 Global RNAi for Therapeutic Revenue by Company (2020-2025)

2.3 Key Companies RNAi for Therapeutic Manufacturing Base Distribution and Headquarters

2.4 Key Companies RNAi for Therapeutic Product Offered

2.5 Key Companies Time to Begin Mass Production of RNAi for Therapeutic

2.6 RNAi for Therapeutic Market Competitive Analysis

2.6.1 RNAi for Therapeutic Market Concentration Rate (2020-2025)

2.6.2 Global 5 and 10 Largest Companies by RNAi for Therapeutic Revenue in 2024

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNAi for Therapeutic as of 2024)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 siRNA

3.1.2 miRNA

3.1.3 shRNA

3.2 Global RNAi for Therapeutic Sales Value by Type

3.2.1 Global RNAi for Therapeutic Sales Value by Type (2020 VS 2024 VS 2031)

3.2.2 Global RNAi for Therapeutic Sales Value, by Type (2020-2031)

3.2.3 Global RNAi for Therapeutic Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Cancer

4.1.2 Cardiovascular

4.1.3 HBV

4.1.4 Others

4.2 Global RNAi for Therapeutic Sales Value by Application

4.2.1 Global RNAi for Therapeutic Sales Value by Application (2020 VS 2024 VS 2031)

4.2.2 Global RNAi for Therapeutic Sales Value, by Application (2020-2031)

4.2.3 Global RNAi for Therapeutic Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

5.1 Global RNAi for Therapeutic Sales Value by Region

5.1.1 Global RNAi for Therapeutic Sales Value by Region: 2020 VS 2024 VS 2031

5.1.2 Global RNAi for Therapeutic Sales Value by Region (2020-2025)

5.1.3 Global RNAi for Therapeutic Sales Value by Region (2026-2031)

5.1.4 Global RNAi for Therapeutic Sales Value by Region (%), (2020-2031)

5.2 North America

5.2.1 North America RNAi for Therapeutic Sales Value, 2020-2031

5.2.2 North America RNAi for Therapeutic Sales Value by Country (%), 2024 VS 2031

5.3 Europe

5.3.1 Europe RNAi for Therapeutic Sales Value, 2020-2031

5.3.2 Europe RNAi for Therapeutic Sales Value by Country (%), 2024 VS 2031

5.4 Asia Pacific

5.4.1 Asia Pacific RNAi for Therapeutic Sales Value, 2020-2031

5.4.2 Asia Pacific RNAi for Therapeutic Sales Value by Region (%), 2024 VS 2031

5.5 South America

5.5.1 South America RNAi for Therapeutic Sales Value, 2020-2031

5.5.2 South America RNAi for Therapeutic Sales Value by Country (%), 2024 VS 2031

5.6 Middle East & Africa

5.6.1 Middle East & Africa RNAi for Therapeutic Sales Value, 2020-2031

5.6.2 Middle East & Africa RNAi for Therapeutic Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions RNAi for Therapeutic Sales Value Growth Trends, 2020 VS 2024 VS 2031

6.2 Key Countries/Regions RNAi for Therapeutic Sales Value, 2020-2031

6.3 United States

6.3.1 United States RNAi for Therapeutic Sales Value, 2020-2031

6.3.2 United States RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031

6.3.3 United States RNAi for Therapeutic Sales Value by Application, 2024 VS 2031

6.4 Europe

6.4.1 Europe RNAi for Therapeutic Sales Value, 2020-2031

6.4.2 Europe RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031

6.4.3 Europe RNAi for Therapeutic Sales Value by Application, 2024 VS 2031

6.5 China

6.5.1 China RNAi for Therapeutic Sales Value, 2020-2031

6.5.2 China RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031

6.5.3 China RNAi for Therapeutic Sales Value by Application, 2024 VS 2031

6.6 Japan

6.6.1 Japan RNAi for Therapeutic Sales Value, 2020-2031

6.6.2 Japan RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031

6.6.3 Japan RNAi for Therapeutic Sales Value by Application, 2024 VS 2031

6.7 South Korea

6.7.1 South Korea RNAi for Therapeutic Sales Value, 2020-2031

6.7.2 South Korea RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031

6.7.3 South Korea RNAi for Therapeutic Sales Value by Application, 2024 VS 2031

6.8 Southeast Asia

6.8.1 Southeast Asia RNAi for Therapeutic Sales Value, 2020-2031

6.8.2 Southeast Asia RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031

6.8.3 Southeast Asia RNAi for Therapeutic Sales Value by Application, 2024 VS 2031

6.9 India

6.9.1 India RNAi for Therapeutic Sales Value, 2020-2031

6.9.2 India RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031

6.9.3 India RNAi for Therapeutic Sales Value by Application, 2024 VS 2031

7 Company Profiles

7.1 Alnylam Pharmaceuticals

7.1.1 Alnylam Pharmaceuticals Profile

7.1.2 Alnylam Pharmaceuticals Main Business

7.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions

7.1.4 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)

7.1.5 Alnylam Pharmaceuticals Recent Developments

7.2 Arbutus Biopharma (Tekmira)

7.2.1 Arbutus Biopharma (Tekmira) Profile

7.2.2 Arbutus Biopharma (Tekmira) Main Business

7.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Products, Services and Solutions

7.2.4 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)

7.2.5 Arbutus Biopharma (Tekmira) Recent Developments

7.3 Arrowhead

7.3.1 Arrowhead Profile

7.3.2 Arrowhead Main Business

7.3.3 Arrowhead RNAi for Therapeutic Products, Services and Solutions

7.3.4 Arrowhead RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)

7.3.5 Arrowhead Recent Developments

7.4 Dicerna Pharmaceuticals

7.4.1 Dicerna Pharmaceuticals Profile

7.4.2 Dicerna Pharmaceuticals Main Business

7.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions

7.4.4 Dicerna Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)

7.4.5 Dicerna Pharmaceuticals Recent Developments

7.5 Mirna Therapeutics

7.5.1 Mirna Therapeutics Profile

7.5.2 Mirna Therapeutics Main Business

7.5.3 Mirna Therapeutics RNAi for Therapeutic Products, Services and Solutions

7.5.4 Mirna Therapeutics RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)

7.5.5 Mirna Therapeutics Recent Developments

7.6 Quark Pharmaceuticals

7.6.1 Quark Pharmaceuticals Profile

7.6.2 Quark Pharmaceuticals Main Business

7.6.3 Quark Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions

7.6.4 Quark Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)

7.6.5 Quark Pharmaceuticals Recent Developments

7.7 RXi Pharmaceuticals

7.7.1 RXi Pharmaceuticals Profile

7.7.2 RXi Pharmaceuticals Main Business

7.7.3 RXi Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions

7.7.4 RXi Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)

7.7.5 RXi Pharmaceuticals Recent Developments

7.8 Silence Therapeutics

7.8.1 Silence Therapeutics Profile

7.8.2 Silence Therapeutics Main Business

7.8.3 Silence Therapeutics RNAi for Therapeutic Products, Services and Solutions

7.8.4 Silence Therapeutics RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)

7.8.5 Silence Therapeutics Recent Developments

7.9 Benitec Biopharma

7.9.1 Benitec Biopharma Profile

7.9.2 Benitec Biopharma Main Business

7.9.3 Benitec Biopharma RNAi for Therapeutic Products, Services and Solutions

7.9.4 Benitec Biopharma RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)

7.9.5 Benitec Biopharma Recent Developments

7.10 miRagen Therapeutics

7.10.1 miRagen Therapeutics Profile

7.10.2 miRagen Therapeutics Main Business

7.10.3 miRagen Therapeutics RNAi for Therapeutic Products, Services and Solutions

7.10.4 miRagen Therapeutics RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)

7.10.5 miRagen Therapeutics Recent Developments

7.11 Sylentis

7.11.1 Sylentis Profile

7.11.2 Sylentis Main Business

7.11.3 Sylentis RNAi for Therapeutic Products, Services and Solutions

7.11.4 Sylentis RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)

7.11.5 Sylentis Recent Developments

7.12 Gradalis

7.12.1 Gradalis Profile

7.12.2 Gradalis Main Business

7.12.3 Gradalis RNAi for Therapeutic Products, Services and Solutions

7.12.4 Gradalis RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)

7.12.5 Gradalis Recent Developments

7.13 Sirnaomics

7.13.1 Sirnaomics Profile

7.13.2 Sirnaomics Main Business

7.13.3 Sirnaomics RNAi for Therapeutic Products, Services and Solutions

7.13.4 Sirnaomics RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)

7.13.5 Sirnaomics Recent Developments

7.14 Silenseed

7.14.1 Silenseed Profile

7.14.2 Silenseed Main Business

7.14.3 Silenseed RNAi for Therapeutic Products, Services and Solutions

7.14.4 Silenseed RNAi for Therapeutic Revenue (US$ Million) & (2020-2025)

7.14.5 Silenseed Recent Developments

8 Industry Chain Analysis

8.1 RNAi for Therapeutic Industrial Chain

8.2 RNAi for Therapeutic Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 RNAi for Therapeutic Sales Model

8.5.2 Sales Channel

8.5.3 RNAi for Therapeutic Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. RNAi for Therapeutic Market Trends

Table 2. RNAi for Therapeutic Market Drivers & Opportunity

Table 3. RNAi for Therapeutic Market Challenges

Table 4. RNAi for Therapeutic Market Restraints

Table 5. Global RNAi for Therapeutic Revenue by Company (2020-2025) & (US$ Million)

Table 6. Global RNAi for Therapeutic Revenue Market Share by Company (2020-2025)

Table 7. Key Companies RNAi for Therapeutic Manufacturing Base Distribution and Headquarters

Table 8. Key Companies RNAi for Therapeutic Product Type

Table 9. Key Companies Time to Begin Mass Production of RNAi for Therapeutic

Table 10. Global RNAi for Therapeutic Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNAi for Therapeutic as of 2024)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global RNAi for Therapeutic Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)

Table 14. Global RNAi for Therapeutic Sales Value by Type (2020-2025) & (US$ Million)

Table 15. Global RNAi for Therapeutic Sales Value by Type (2026-2031) & (US$ Million)

Table 16. Global RNAi for Therapeutic Sales Market Share in Value by Type (2020-2025)

Table 17. Global RNAi for Therapeutic Sales Market Share in Value by Type (2026-2031)

Table 18. Global RNAi for Therapeutic Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)

Table 19. Global RNAi for Therapeutic Sales Value by Application (2020-2025) & (US$ Million)

Table 20. Global RNAi for Therapeutic Sales Value by Application (2026-2031) & (US$ Million)

Table 21. Global RNAi for Therapeutic Sales Market Share in Value by Application (2020-2025)

Table 22. Global RNAi for Therapeutic Sales Market Share in Value by Application (2026-2031)

Table 23. Global RNAi for Therapeutic Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)

Table 24. Global RNAi for Therapeutic Sales Value by Region (2020-2025) & (US$ Million)

Table 25. Global RNAi for Therapeutic Sales Value by Region (2026-2031) & (US$ Million)

Table 26. Global RNAi for Therapeutic Sales Value by Region (2020-2025) & (%)

Table 27. Global RNAi for Therapeutic Sales Value by Region (2026-2031) & (%)

Table 28. Key Countries/Regions RNAi for Therapeutic Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031

Table 29. Key Countries/Regions RNAi for Therapeutic Sales Value, (2020-2025) & (US$ Million)

Table 30. Key Countries/Regions RNAi for Therapeutic Sales Value, (2026-2031) & (US$ Million)

Table 31. Alnylam Pharmaceuticals Basic Information List

Table 32. Alnylam Pharmaceuticals Description and Business Overview

Table 33. Alnylam Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions

Table 34. Revenue (US$ Million) in RNAi for Therapeutic Business of Alnylam Pharmaceuticals (2020-2025)

Table 35. Alnylam Pharmaceuticals Recent Developments

Table 36. Arbutus Biopharma (Tekmira) Basic Information List

Table 37. Arbutus Biopharma (Tekmira) Description and Business Overview

Table 38. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Products, Services and Solutions

Table 39. Revenue (US$ Million) in RNAi for Therapeutic Business of Arbutus Biopharma (Tekmira) (2020-2025)

Table 40. Arbutus Biopharma (Tekmira) Recent Developments

Table 41. Arrowhead Basic Information List

Table 42. Arrowhead Description and Business Overview

Table 43. Arrowhead RNAi for Therapeutic Products, Services and Solutions

Table 44. Revenue (US$ Million) in RNAi for Therapeutic Business of Arrowhead (2020-2025)

Table 45. Arrowhead Recent Developments

Table 46. Dicerna Pharmaceuticals Basic Information List

Table 47. Dicerna Pharmaceuticals Description and Business Overview

Table 48. Dicerna Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions

Table 49. Revenue (US$ Million) in RNAi for Therapeutic Business of Dicerna Pharmaceuticals (2020-2025)

Table 50. Dicerna Pharmaceuticals Recent Developments

Table 51. Mirna Therapeutics Basic Information List

Table 52. Mirna Therapeutics Description and Business Overview

Table 53. Mirna Therapeutics RNAi for Therapeutic Products, Services and Solutions

Table 54. Revenue (US$ Million) in RNAi for Therapeutic Business of Mirna Therapeutics (2020-2025)

Table 55. Mirna Therapeutics Recent Developments

Table 56. Quark Pharmaceuticals Basic Information List

Table 57. Quark Pharmaceuticals Description and Business Overview

Table 58. Quark Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions

Table 59. Revenue (US$ Million) in RNAi for Therapeutic Business of Quark Pharmaceuticals (2020-2025)

Table 60. Quark Pharmaceuticals Recent Developments

Table 61. RXi Pharmaceuticals Basic Information List

Table 62. RXi Pharmaceuticals Description and Business Overview

Table 63. RXi Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions

Table 64. Revenue (US$ Million) in RNAi for Therapeutic Business of RXi Pharmaceuticals (2020-2025)

Table 65. RXi Pharmaceuticals Recent Developments

Table 66. Silence Therapeutics Basic Information List

Table 67. Silence Therapeutics Description and Business Overview

Table 68. Silence Therapeutics RNAi for Therapeutic Products, Services and Solutions

Table 69. Revenue (US$ Million) in RNAi for Therapeutic Business of Silence Therapeutics (2020-2025)

Table 70. Silence Therapeutics Recent Developments

Table 71. Benitec Biopharma Basic Information List

Table 72. Benitec Biopharma Description and Business Overview

Table 73. Benitec Biopharma RNAi for Therapeutic Products, Services and Solutions

Table 74. Revenue (US$ Million) in RNAi for Therapeutic Business of Benitec Biopharma (2020-2025)

Table 75. Benitec Biopharma Recent Developments

Table 76. miRagen Therapeutics Basic Information List

Table 77. miRagen Therapeutics Description and Business Overview

Table 78. miRagen Therapeutics RNAi for Therapeutic Products, Services and Solutions

Table 79. Revenue (US$ Million) in RNAi for Therapeutic Business of miRagen Therapeutics (2020-2025)

Table 80. miRagen Therapeutics Recent Developments

Table 81. Sylentis Basic Information List

Table 82. Sylentis Description and Business Overview

Table 83. Sylentis RNAi for Therapeutic Products, Services and Solutions

Table 84. Revenue (US$ Million) in RNAi for Therapeutic Business of Sylentis (2020-2025)

Table 85. Sylentis Recent Developments

Table 86. Gradalis Basic Information List

Table 87. Gradalis Description and Business Overview

Table 88. Gradalis RNAi for Therapeutic Products, Services and Solutions

Table 89. Revenue (US$ Million) in RNAi for Therapeutic Business of Gradalis (2020-2025)

Table 90. Gradalis Recent Developments

Table 91. Sirnaomics Basic Information List

Table 92. Sirnaomics Description and Business Overview

Table 93. Sirnaomics RNAi for Therapeutic Products, Services and Solutions

Table 94. Revenue (US$ Million) in RNAi for Therapeutic Business of Sirnaomics (2020-2025)

Table 95. Sirnaomics Recent Developments

Table 96. Silenseed Basic Information List

Table 97. Silenseed Description and Business Overview

Table 98. Silenseed RNAi for Therapeutic Products, Services and Solutions

Table 99. Revenue (US$ Million) in RNAi for Therapeutic Business of Silenseed (2020-2025)

Table 100. Silenseed Recent Developments

Table 101. Key Raw Materials Lists

Table 102. Raw Materials Key Suppliers Lists

Table 103. RNAi for Therapeutic Downstream Customers

Table 104. RNAi for Therapeutic Distributors List

Table 105. Research Programs/Design for This Report

Table 106. Key Data Information from Secondary Sources

Table 107. Key Data Information from Primary Sources

Table 108. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. RNAi for Therapeutic Product Picture

Figure 2. Global RNAi for Therapeutic Sales Value, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Global RNAi for Therapeutic Sales Value (2020-2031) & (US$ Million)

Figure 4. RNAi for Therapeutic Report Years Considered

Figure 5. Global RNAi for Therapeutic Players Revenue Ranking (2024) & (US$ Million)

Figure 6. The 5 and 10 Largest Companies in the World: Market Share by RNAi for Therapeutic Revenue in 2024

Figure 7. RNAi for Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 8. siRNA Picture

Figure 9. miRNA Picture

Figure 10. shRNA Picture

Figure 11. Global RNAi for Therapeutic Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)

Figure 12. Global RNAi for Therapeutic Sales Value Market Share by Type, 2024 & 2031

Figure 13. Product Picture of Cancer

Figure 14. Product Picture of Cardiovascular

Figure 15. Product Picture of HBV

Figure 16. Product Picture of Others

Figure 17. Global RNAi for Therapeutic Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)

Figure 18. Global RNAi for Therapeutic Sales Value Market Share by Application, 2024 & 2031

Figure 19. North America RNAi for Therapeutic Sales Value (2020-2031) & (US$ Million)

Figure 20. North America RNAi for Therapeutic Sales Value by Country (%), 2024 VS 2031

Figure 21. Europe RNAi for Therapeutic Sales Value, (2020-2031) & (US$ Million)

Figure 22. Europe RNAi for Therapeutic Sales Value by Country (%), 2024 VS 2031

Figure 23. Asia Pacific RNAi for Therapeutic Sales Value, (2020-2031) & (US$ Million)

Figure 24. Asia Pacific RNAi for Therapeutic Sales Value by Region (%), 2024 VS 2031

Figure 25. South America RNAi for Therapeutic Sales Value, (2020-2031) & (US$ Million)

Figure 26. South America RNAi for Therapeutic Sales Value by Country (%), 2024 VS 2031

Figure 27. Middle East & Africa RNAi for Therapeutic Sales Value, (2020-2031) & (US$ Million)

Figure 28. Middle East & Africa RNAi for Therapeutic Sales Value by Country (%), 2024 VS 2031

Figure 29. Key Countries/Regions RNAi for Therapeutic Sales Value (%), (2020-2031)

Figure 30. United States RNAi for Therapeutic Sales Value, (2020-2031) & (US$ Million)

Figure 31. United States RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031

Figure 32. United States RNAi for Therapeutic Sales Value by Application (%), 2024 VS 2031

Figure 33. Europe RNAi for Therapeutic Sales Value, (2020-2031) & (US$ Million)

Figure 34. Europe RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031

Figure 35. Europe RNAi for Therapeutic Sales Value by Application (%), 2024 VS 2031

Figure 36. China RNAi for Therapeutic Sales Value, (2020-2031) & (US$ Million)

Figure 37. China RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031

Figure 38. China RNAi for Therapeutic Sales Value by Application (%), 2024 VS 2031

Figure 39. Japan RNAi for Therapeutic Sales Value, (2020-2031) & (US$ Million)

Figure 40. Japan RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031

Figure 41. Japan RNAi for Therapeutic Sales Value by Application (%), 2024 VS 2031

Figure 42. South Korea RNAi for Therapeutic Sales Value, (2020-2031) & (US$ Million)

Figure 43. South Korea RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031

Figure 44. South Korea RNAi for Therapeutic Sales Value by Application (%), 2024 VS 2031

Figure 45. Southeast Asia RNAi for Therapeutic Sales Value, (2020-2031) & (US$ Million)

Figure 46. Southeast Asia RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031

Figure 47. Southeast Asia RNAi for Therapeutic Sales Value by Application (%), 2024 VS 2031

Figure 48. India RNAi for Therapeutic Sales Value, (2020-2031) & (US$ Million)

Figure 49. India RNAi for Therapeutic Sales Value by Type (%), 2024 VS 2031

Figure 50. India RNAi for Therapeutic Sales Value by Application (%), 2024 VS 2031

Figure 51. RNAi for Therapeutic Industrial Chain

Figure 52. RNAi for Therapeutic Manufacturing Cost Structure

Figure 53. Channels of Distribution (Direct Sales, and Distribution)

Figure 54. Bottom-up and Top-down Approaches for This Report

Figure 55. Data Triangulation

Figure 56. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which companies rank high in the global RNAi for Therapeutic market? zhanKai

The top companies in the global RNAi for Therapeutic market are Alnylam Pharmaceuticals、Arbutus Biopharma (Tekmira)、Arrowhead.

Which region is expected to have the highest market share? shouQi

What was the global market size of RNAi for Therapeutic in 2025? shouQi

What is the annual compound growth rate of the global RNAi for Therapeutic market size from 2025 to 2031? shouQi

What was the global market size of RNAi for Therapeutic in 2031? shouQi

Related Reports

Global RNAi for Therapeutic Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global RNAi for Therapeutic market size was US$ 3058 million in 2025 and is forecast to reach a readjusted size of US$ 16370 million by 2032 with a CAGR of 27.5% during the forecast period 2026-2032.
Published Date: 2026-01-04
Pages: 100
USD 4250.00
(Single User License)
Global RNAi for Therapeutic Market Research Report 2026
The global RNAi for Therapeutic market was valued at US$ 3058 million in 2025 and is anticipated to reach US$ 16370 million by 2032, at a CAGR of 27.5% from 2026 to 2032.
Published Date: 2026-01-04
Pages: 115
USD 2900.00
(Single User License)
RNAi for Therapeutic - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for RNAi for Therapeutic was estimated to be worth US$ 3058 million in 2025 and is projected to reach US$ 16370 million, growing at a CAGR of 27.5% from 2026 to 2032.
Published Date: 2026-01-04
Pages: 111
USD 3950.00
(Single User License)
RNAi for Therapeutic - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for RNAi for Therapeutic was estimated to be worth US$ 2278 million in 2024 and is forecast to a readjusted size of US$ 13125 million by 2031 with a CAGR of 27.5% during the forecast period 2025-2031.
Published Date: 2025-10-21
Pages: 114
USD 3950.00
(Single User License)
Global RNAi for Therapeutic Market Outlook, In‑Depth Analysis & Forecast to 2031
The global RNAi for Therapeutic market is projected to grow from US$ 2278 million in 2024 to US$ 13125 million by 2031, at a CAGR of 27.5% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-09-11
Pages: 132
USD 4900.00
(Single User License)
Global RNAi for Therapeutic Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global RNAi for Therapeutic market size was US$ 2278 million in 2024 and is forecast to a readjusted size of US$ 13125 million by 2031 with a CAGR of 27.5% during the forecast period 2025-2031.
Published Date: 2025-08-13
Pages: 97
USD 4250.00
(Single User License)
Global RNAi for Therapeutic Market Research Report 2025
The global market for RNAi for Therapeutic was valued at US$ 2278 million in the year 2024 and is projected to reach a revised size of US$ 13125 million by 2031, growing at a CAGR of 27.5% during the forecast period.
Published Date: 2025-08-13
Pages: 84
USD 2900.00
(Single User License)
Global RNAi for Therapeutic Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of RNAi for Therapeutic was estimated to be worth US$ 358 million and is forecast to reach approximately US$ 4272 million by 2031 with a CAGR of 43.1% during the forecast period 2025-2031.
Published Date: 2025-03-28
Pages: 145
USD 5900.00
(Single User License)
Global RNAi for Therapeutic Industry Research Report, Growth Trends and Competitive Analysis 2024-2030
RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
Published Date: 2024-04-17
Pages: 159
USD 5600.00
(Single User License)
Global RNAi for Therapeutic Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030
RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
Published Date: 2024-04-16
Pages: 150
USD 5900.00
(Single User License)

Global RNAi for Therapeutic Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global RNAi for Therapeutic market size was US$ 3058 million in 2025 and is forecast to reach a readjusted size of US$ 16370 million by 2032 with a CAGR of 27.5% during the forecast period 2026-2032.
Published: 2026-01-04
Pages: 100
USD 4250.00 (Single User License)
Global RNAi for Therapeutic Market Research Report 2026
The global RNAi for Therapeutic market was valued at US$ 3058 million in 2025 and is anticipated to reach US$ 16370 million by 2032, at a CAGR of 27.5% from 2026 to 2032.
Published: 2026-01-04
Pages: 115
USD 2900.00 (Single User License)
RNAi for Therapeutic - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for RNAi for Therapeutic was estimated to be worth US$ 3058 million in 2025 and is projected to reach US$ 16370 million, growing at a CAGR of 27.5% from 2026 to 2032.
Published: 2026-01-04
Pages: 111
USD 3950.00 (Single User License)
RNAi for Therapeutic - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for RNAi for Therapeutic was estimated to be worth US$ 2278 million in 2024 and is forecast to a readjusted size of US$ 13125 million by 2031 with a CAGR of 27.5% during the forecast period 2025-2031.
Published: 2025-10-21
Pages: 114
USD 3950.00 (Single User License)
Global RNAi for Therapeutic Market Outlook, In‑Depth Analysis & Forecast to 2031
The global RNAi for Therapeutic market is projected to grow from US$ 2278 million in 2024 to US$ 13125 million by 2031, at a CAGR of 27.5% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-09-11
Pages: 132
USD 4900.00 (Single User License)
Global RNAi for Therapeutic Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global RNAi for Therapeutic market size was US$ 2278 million in 2024 and is forecast to a readjusted size of US$ 13125 million by 2031 with a CAGR of 27.5% during the forecast period 2025-2031.
Published: 2025-08-13
Pages: 97
USD 4250.00 (Single User License)
Global RNAi for Therapeutic Market Research Report 2025
The global market for RNAi for Therapeutic was valued at US$ 2278 million in the year 2024 and is projected to reach a revised size of US$ 13125 million by 2031, growing at a CAGR of 27.5% during the forecast period.
Published: 2025-08-13
Pages: 84
USD 2900.00 (Single User License)
Global RNAi for Therapeutic Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of RNAi for Therapeutic was estimated to be worth US$ 358 million and is forecast to reach approximately US$ 4272 million by 2031 with a CAGR of 43.1% during the forecast period 2025-2031.
Published: 2025-03-28
Pages: 145
USD 5900.00 (Single User License)
Global RNAi for Therapeutic Industry Research Report, Growth Trends and Competitive Analysis 2024-2030
RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
Published: 2024-04-17
Pages: 159
USD 5600.00 (Single User License)
Global RNAi for Therapeutic Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030
RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
Published: 2024-04-16
Pages: 150
USD 5900.00 (Single User License)